Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q4 2024 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. Look for comparisons against own past, already real and recurring, early stage. In the transcript, management discusses launches of new brands like Donna Karan, Nautica, Halston, Champion. They talk about growth of owned brands. But the question is about "successive engagements of the same kind" — e.g., orders, contracts, projects, customers, sites, programs. Does management say that the size of individual deals or orders is escalating? They mention that Donna Karan product commands higher AURs, and retailers have increased their buys for second half. But that's about price and volume, not necessarily unit size of engagements. They talk about expanding into new categories, new doors, but not specifically that each new order is larger than previous ones. They mention "we're working with new distribution partners to grow into new categories" — that's expansion, not necessarily larger individual deals. They mention "we see a $1 billion annual sales opportunity" for brands, but that's potential, not current. They mention "our order book is strong" and "growing in Donna Karan" but no explicit comparison of average order size increasing. They mention "retailers have already increased their buys for the second half of the year" — that could be interpreted as larger orders, but it's about volume, not necessarily unit size of each engagement. Also, it's about a new brand launch, not a repeatable business where each successive engagement is larger. The question asks: "does management convey that the deals, orders, contracts, projects, customers, sites, or programs it is landing NOW are individually bigger, broader, or longer than the ones it was landing for the same offering not long ago" — I don't see that. They talk about growth in sales, but not about the size of individual orders increasing. They talk about expanding into new categories, but that's scope, not necessarily larger per engagement. They mention "we're also selling to the brands global distribution network" for Nautica, but that's distribution. No clear statement like "average order size has increased" or "new customers are starting at higher levels." Thus answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.